AbbVie study data further demonstrates benefits of Elagolix

AbbVie has announced new clinical trial data offering further evidence of the benefits its drug Elagolix can provide for endometriosis patients.

Results from two replicate pivotal phase III clinical trials have been presented that demonstrate the efficacy and safety of Elagolix in premenopausal women compared to placebo after three and six months of treatment.

Patients treated with Elagolix were shown to experience statistically significant reductions in scores for menstrual pain and non-menstrual pelvic pain associated with endometriosis. Meanwhile, the safety profile of the drug was consistent across both phase III trials and also with prior Elagolix studies.

Nearly 1,700 patients were involved in the two pivotal trials, making them the largest endometriosis studies conducted to date.

Dr Rob Scott, vice-president for development and chief medical officer at AbbVie, said: "There have been few recent scientific advancements for patients suffering from endometriosis and physicians are in need of additional treatment options to help manage this chronic and painful disease."

Elagolix has been studied in over 40 clinical trials totaling more than 3,000 subjects to date.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.